Showing 1551-1560 of 5062 results for "".
- Merz Aesthetics Rolls Out “Confidence to Be” Branding Platform and Other Changeshttps://practicaldermatology.com/news/merz-aesthetics-rolls-outconfidence-to-be-branding-platform-and-other-changes/2460497/Merz Aesthetics is launching its new “confidence to be” branding platform following the conclusion of the company’s reorganization. Merz is now three independently operating businesses: medical aesthetics, therapeutics and consumer care. “The new brand
- Third Pivotal Phase 3 Study Shows Rinvoq Plus Topical Corticosteroids Improves Skin and Itch Symptoms in Atopic Dermatitishttps://practicaldermatology.com/news/third-pivotal-phase-3-study-shows-rinvoq-plus-topical-corticosteroids-improves-skin-and-itch-symptoms-in-atopic-dermatitis/2460489/AbbVie's upadacitinib (15 mg and 30 mg, once daily) (Rinvoq) plus topical corticosteroids (TCS) met the co-primary endpoints and all secondary endpoints in AD Up, the third pivotal Phase 3 study of Rinvoq in atopic dermatitis. AD Up evaluated the efficacy and safety of both doses of upadaciti
- Rihanna Introduces Fenty Skinhttps://practicaldermatology.com/news/rihanna-introduces-fenty-skin/2460487/Rihanna, in partnership with Kendo Brands, is rolling out Fenty Skin. After years of feeling overwhelmed by all the skincare choices and a bad experience with a product that discolored her skin as a teen, Rihanna dreamed of creating a line that was easy and effective. Now, she'
- Meet Amber Edwards, Alastin Skincare’s New Chief Commercial Officerhttps://practicaldermatology.com/news/meet-amber-edwards-alastin-skincares-new-chief-commercial-officer/2460485/Amber Edwards is Alastin Skincare’s new Chief Commercial Officer, effective July 31, 2020 Ms. Edwards most recently served as President of North America for Sinclair Pharma. Prior to Sinclair, she was at Allergan, Inc. where she was the Vice President of International Strategic Ma
- Genentech’s Tecentriq plus Cotellic and Zelboraf Approved for Advanced Melanomahttps://practicaldermatology.com/news/genentechs-tecentriq-plus-cotellic-and-zelboraf-approved-for-advanced-melanoma/2460483/Tecentriq (atezolizumab) is now approved in combination with Cotellic (cobimetinib) and Zelboraf(vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. The safety profile observed in the Tecentriq combination was consistent with the known safety profil
- George W. Mahaffey Named CEO of Mindera Corporationhttps://practicaldermatology.com/news/george-w-mahaffey-named-ceo-of-mindera-corporation/2460480/George W. Mahaffey is the new President and Chief Executive Officer of Mindera Corporation. He will also serve as a Director of the Company. Mindera has developed a novel platform to extract thousands of biomarkers from an individual patient via a dermal biomarker patch. Captured R
- Bimekizumab Bests Cosentyx in Achieving Complete Psoriasis Skin Clearancehttps://practicaldermatology.com/news/bimekizumab-bests-cosentyx-in-achieving-complete-psoriasis-skin-clearance/2460478/UCB’s investigational IL-17A and IL-17F inhibitor bimekizumab outperformed the IL-17A inhibitor Cosentyx (secukinumab) in a head-to-head Phase 3 b study of adult patients with moderate-to-severe plaque psoriasis. This is the first head-to-head study comparing a
- Win for MC2 Therapeutics: Wynzora Cream Approved for Adults with Psoriasishttps://practicaldermatology.com/news/win-for-mc2-therapeutics-wynzora-cream-approved-for-adults-with-psoriasis/2460476/FDA has approved Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) from MC2 Therapeutics for once-daily topical treatment of plaque psoriasis in adults 18 years of age or older. The approval is based on results of the US Phase 3 clinical trial&nbs
- Abbvie's Rinvoq Monotherapy Meets All Primary and Secondary Endpoints in Second Phase 3 Study for Atopic Dermatitishttps://practicaldermatology.com/news/abbvies-rinvoq-monotherapy-meets-all-primary-and-secondary-endpoints-in-second-phase-3-study-for-atopic-dermatitis/2460475/AbbVie's upadacitinib (Rinvoq) (15 mg and 30 mg, once daily) monotherapy met both primary and all secondary endpoints in Measure Up 2, the second Phase 3 study in individuals with moderate to severe atopic dermatitis. The co-primary endpoints were at least a 75 percent improvement in the Ecze
- Study: Pembrolizumab Provides Long-Term Benefits in Patients With Metastatic Melanomahttps://practicaldermatology.com/news/study-pembrolizumab-provides-long-term-benefits-in-patients-with-metastatic-melanoma/2460470/A new 10-year analysis provides new insights into an important question: whether BRAF V600E/K mutation status or previous BRAF inhibitor (BRAFi) therapy with or without a MEK inhibitor (MEKi) affects response to pembrolizumab (Keytruda). This retrospective analysis of three ra